Table A1.
Univariate analysis results.
| Overall Survival | Local Failure | Distant Failure | ||||
|---|---|---|---|---|---|---|
| Factor | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value |
| Age at diagnosis | 1.02 (1.01–1.03) | 0.005 | − | − | − | − |
| KPS | ||||||
| <80 | 1 [Reference] | − | − | − | − | |
| ≥80 | 0.58 (0.45–0.75) | <0.001 | − | − | − | − |
| History of smoking | ||||||
| Former | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| Current | 1.04 (0.81–1.35) | 0.75 | 1.04 (0.7– 1.46) | 0.83 | 1.14 (0.83–1.57) | 0.43 |
| Never | 0.85 (0.52–1.41) | 0.53 | 1.88 (1.19–2.98) | 0.007 | 1.63 (0.98–2.70) | 0.06 |
| T stage | ||||||
| T1 | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| T2 | 1.34 (0.97–1.83) | 0.08 | 1.58 (1.04–2.41) | 0.03 | 1.19 (0.82–1.73) | 0.37 |
| T3 | 1.55 (1.10–2.19) | 0.01 | 1.87 (1.21–2.88) | 0.005 | 1.23 (0.82–1.86) | 0.32 |
| T4 | 1.76 (1.20–2.59) | 0.004 | 1.30 (0.78–2.19) | 0.32 | 1.02 (0.63–1.66) | 0.94 |
| Tx | 0.69 (0.35–1.40) | 0.30 | 0.61 (0.19–1.93) | 0.40 | 0.38 (0.13–1.11) | 0.08 |
| N stage | ||||||
| N0 | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| N1 | 0.79 (0.48–1.30) | 0.35 | 0.76 (0.42–1.38) | 0.36 | 1.61 (0.81–3.19) | 0.17 |
| N2 | 0.89 (0.59–1.34) | 0.58 | 0.75 (0.46–1.22) | 0.25 | 1.48 (0.80–2.74) | 0.21 |
| N3 | 0.66 (0.43–1.03) | 0.07 | 0.96 (0.58–1.59) | 0.88 | 1.99 (1.06–3.71) | 0.03 |
| Stage | ||||||
| IIA | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| IIB | 1.39 (0.75–2.58) | 0.30 | 2.68 (1.25–5.74) | 0.01 | 0.83 (0.36–1.90) | 0.65 |
| IIIA | 0.96 (0.61–1.50) | 0.86 | 1.10 (0.58–2.08) | 0.76 | 0.84 (0.49–1.44) | 0.53 |
| IIIB | 0.90 (0.56–1.43) | 0.65 | 1.51 (0.80–2.87) | 0.21 | 1.25 (0.73–2.15) | 0.42 |
| Histology | ||||||
| Squamous cell | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| Adenocarconima | 0.73 (0.57–0.95) | 0.02 | 0.89 (0.64–1.24) | 0.50 | 1.68 (1.21–2.33) | 0.002 |
| Other/NOS | 0.91 (0.64–1.31) | 0.63 | 1.12 (0.70–1.79) | 0.65 | 1.36 (0.82–2.24) | 0.23 |
| Histologic grade | ||||||
| Moderate | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| Poor | 1.27 (0.86–1.87) | 0.22 | 1.03 (0.63–1.68) | 0.91 | 0.73 (0.48–1.11) | 0.14 |
| Unknown | 1.08 (0.74–1.59) | 0.68 | 0.98 (0.61–1.58) | 0.93 | 0.61 (0.40–0.91) | 0.02 |
| Primary site | ||||||
| RML/RLL/LLL | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| RUL/LUL | 1.08 (0.84–1.39) | 0.54 | 1.01 (0.73–1.38) | 0.96 | 1.20 (0.88–1.62) | 0.25 |
| Radiation dose, Gy | ||||||
| <60.0 | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| 60.0 to 66.0 | 0.73 (0.53–1.01) | 0.055 | 0.76 (0.51–1.13) | 0.17 | 0.71 (0.49–1.04) | 0.08 |
| >66.0 | 0.67 (0.48–0.93) | 0.02 | 0.57 (0.36–0.88) | 0.01 | 0.62 (0.41–0.95) | 0.03 |
| RT technique | ||||||
| IMRT | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| 3D-CRT | 1.47 (1.12–1.92) | 0.005 | 0.91 (0.63–1.31) | 0.61 | 0.67 (0.46–0.97) | 0.03 |
| GTV | 1.45 (1.28–1.66)* | <0.001* | 1.08 (0.93–1.25)* | 0.30* | 1.22 (1.06–1.41)* | 0.006* |
| Primary tumor radiographic size | 0.93 (0.76–1.13)* | 0.46* | 1.73 (1.28–2.35)* | 0.004* | 1.31 (0.99–1.74)* | 0.06* |
| Treatment modality | ||||||
| Definitive RT only | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| Sequential CRT | 0.54 (0.42–0.70) | <0.0001 | 1.20 (0.84–1.71) | 0.32 | 1.57 (1.09–2.25) | 0.02 |
KPS: Karnofsky performance status, GTV: primary and nodal gross tumor volume, NOS: not otherwise specified, RT: radiotherapy, CRT: chemoradiation, 3D-CRT: three-dimensional conformal radiation therapy, IMRT: intensity-modulated radiation therapy, Gy: Gray
*
based on log transformed data.